{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:55:47Z","timestamp":1771480547454,"version":"3.50.1"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low-dose cyclophosphamide (LDC) induces selective apoptosis of endothelial cells within the vascular bed of tumors. Here, we investigated a hypothesis that the effect of LDC is mediated by the pro-apoptotic action of endogenous inhibitors of angiogenesis. Tumors treated with LDC demonstrate similar expression of matrix metalloproteinases and also basement membrane-derived angiogenesis inhibitors when compared with wild-type tumors, whereas the expression of thrombospondin-1 (TSP-1) is significantly elevated in LDC-treated tumors. We used mice with an absence of type XVIII collagen (endostatin) or type IV collagen \u03b13 chain (tumstatin) or TSP-1 to assess the contribution of these endogenous inhibitors of angiogenesis on LDC-mediated tumor suppression. Lack of TSP-1 in the host in addition to tumor cells leads to diminished capacity of LDC to suppress tumor growth, whereas the absence of endostatin and tumstatin did not alter the effect of LDC. LDC treatment predominantly induces selective expression of TSP-1 in tumor cells and peri-vascular cells and facilitates apoptosis of proliferating endothelial cells, with minimal direct effect on tumor cells and peri-vascular cells. These studies indicate that TSP-1 contributes to tumor growth suppression induced by LDC and suggest that tumors that express high basal level of TSP-1 may be more susceptible to tumor suppression by such a regimen. This study also makes a strong case for TSP-1 expression levels as a potential predictive marker for the successful use of LDC in cancer patients.<\/jats:p>","DOI":"10.1158\/0008-5472.can-03-3126","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T22:37:34Z","timestamp":1127255854000},"page":"1570-1574","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression"],"prefix":"10.1158","volume":"64","author":[{"given":"Yuki","family":"Hamano","sequence":"first","affiliation":[{"name":"1Center for Matrix Biology, Department of Medicine and the Cancer Center, and"}]},{"given":"Hikaru","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"1Center for Matrix Biology, Department of Medicine and the Cancer Center, and"}]},{"given":"Mary A.","family":"Soubasakos","sequence":"additional","affiliation":[{"name":"1Center for Matrix Biology, Department of Medicine and the Cancer Center, and"}]},{"given":"Mark","family":"Kieran","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School; and"}]},{"given":"Bjorn R.","family":"Olsen","sequence":"additional","affiliation":[{"name":"4Department of Cell Biology, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Jack","family":"Lawler","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School;"}]},{"given":"Akulapalli","family":"Sudhakar","sequence":"additional","affiliation":[{"name":"1Center for Matrix Biology, Department of Medicine and the Cancer Center, and"}]},{"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[{"name":"1Center for Matrix Biology, Department of Medicine and the Cancer Center, and"}]}],"member":"1086","published-online":{"date-parts":[[2004,3,2]]},"reference":[{"key":"2022061620132026700_B1","unstructured":"Browder T., Butterfield C. E., Kraling B. M., Shi B., Marshall B., O\u2019Reilly M. S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60:\u20081878-1886, \u20082000."},{"key":"2022061620132026700_B2","doi-asserted-by":"crossref","unstructured":"Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D. J., Bohlen P., Kerbel R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105:\u2008R15-R24, \u20082000.","DOI":"10.1172\/JCI8829"},{"key":"2022061620132026700_B3","doi-asserted-by":"crossref","unstructured":"Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig., 105:\u20081045-1047, \u20082000.","DOI":"10.1172\/JCI9872"},{"key":"2022061620132026700_B4","unstructured":"Man S., Bocci G., Francia G., Green S. K., Jothy S., Hanahan D., Bohlen P., Hicklin D. J., Bergers G., Kerbel R. S. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res., 62:\u20082731-2735, \u20082002."},{"key":"2022061620132026700_B5","unstructured":"Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R. S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res., 63:\u20084342-4346, \u20082003."},{"key":"2022061620132026700_B6","unstructured":"Bocci G., Nicolaou K. C., Kerbel R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res., 62:\u20086938-6943, \u20082002."},{"key":"2022061620132026700_B7","doi-asserted-by":"crossref","unstructured":"Rodriguez-Manzaneque J. C., Lane T. F., Ortega M. A., Hynes R. O., Lawler J., Iruela-Arispe M. L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 98:\u200812485-12490, \u20082001.","DOI":"10.1073\/pnas.171460498"},{"key":"2022061620132026700_B8","doi-asserted-by":"crossref","unstructured":"Hawighorst T., Velasco P., Streit M., Hong Y. K., Kyriakides T. R., Brown L. F., Bornstein P., Detmar M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J., 20:\u20082631-2640, \u20082001.","DOI":"10.1093\/emboj\/20.11.2631"},{"key":"2022061620132026700_B9","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79:\u2008315-328, \u20081994.","DOI":"10.1016\/0092-8674(94)90200-3"},{"key":"2022061620132026700_B10","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88:\u2008277-285, \u20081997.","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"2022061620132026700_B11","unstructured":"Colorado P. C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E. D., Herman S., Ericksen M. B., Dhanabal M., Simons M., Post M., Kufe D. W., Weichselbaum R. R., Sukhatme V. P., Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res., 60:\u20082520-2526, \u20082000."},{"key":"2022061620132026700_B12","doi-asserted-by":"crossref","unstructured":"Kamphaus G. D., Colorado P. C., Panka D. J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J. W., Sukhatme V. P., Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem., 275:\u20081209-1215, \u20082000.","DOI":"10.1074\/jbc.275.2.1209"},{"key":"2022061620132026700_B13","doi-asserted-by":"crossref","unstructured":"Maeshima Y., Colorado P. C., Torre A., Holthaus K. A., Grunkemeyer J. A., Ericksen M. D., Hopfer H., Xiao Y., Stillman I. E., Kalluri R. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem., 275:\u200821340-21348, \u20082000.","DOI":"10.1074\/jbc.M001956200"},{"key":"2022061620132026700_B14","doi-asserted-by":"crossref","unstructured":"Hamano Y., Zeisberg M., Sugimoto H., Lively J. C., Maeshima Y., Yang C., Hynes R. O., Werb Z., Sudhakar A., Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV \u03b13 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via \u03b1V\u03b23 integrin. Cancer Cell, 3:\u2008589-601, \u20082003.","DOI":"10.1016\/S1535-6108(03)00133-8"},{"key":"2022061620132026700_B15","doi-asserted-by":"crossref","unstructured":"Lawler J., Miao W. M., Duquette M., Bouck N., Bronson R. T., Hynes R. O. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol., 159:\u20081949-1956, \u20082001.","DOI":"10.1016\/S0002-9440(10)63042-8"},{"key":"2022061620132026700_B16","doi-asserted-by":"crossref","unstructured":"Fukai N., Eklund L., Marneros A. G., Oh S. P., Keene D. R., Tamarkin L., Niemela M., Ilves M., Li E., Pihlajaniemi T., Olsen B. R. Lack of collagen XVIII\/endostatin results in eye abnormalities. EMBO J., 21:\u20081535-1544, \u20082002.","DOI":"10.1093\/emboj\/21.7.1535"},{"key":"2022061620132026700_B17","doi-asserted-by":"crossref","unstructured":"Darland D. C., D\u2019Amore P. A. TGF-\u03b2 is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1\/2 and endothelial cells. Angiogenesis, 4:\u200811-20, \u20082001.","DOI":"10.1023\/A:1016611824696"},{"key":"2022061620132026700_B18","doi-asserted-by":"crossref","unstructured":"Lawler J., Sunday M., Thibert V., Duquette M., George E. L., Rayburn H., Hynes R. O. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J. Clin. Investig., 101:\u2008982-992, \u20081998.","DOI":"10.1172\/JCI1684"},{"key":"2022061620132026700_B19","doi-asserted-by":"crossref","unstructured":"Flowers J. L., Ludeman S. M., Gamcsik M. P., Colvin O. M., Shao K. L., Boal J. H., Springer J. B., Adams D. J. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother. Pharmacol., 45:\u2008335-344, \u20082000.","DOI":"10.1007\/s002800050049"},{"key":"2022061620132026700_B20","doi-asserted-by":"crossref","unstructured":"Strutz F., Okada H., Lo C. W., Danoff T., Carone R. L., Tomaszewski J. E., Neilson E. G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol., 130:\u2008393-405, \u20081995.","DOI":"10.1083\/jcb.130.2.393"},{"key":"2022061620132026700_B21","doi-asserted-by":"crossref","unstructured":"Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin. Arthritis Rheum., 12:\u2008359-372, \u20081983.","DOI":"10.1016\/0049-0172(83)90016-1"},{"key":"2022061620132026700_B22","doi-asserted-by":"crossref","unstructured":"Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer, 3:\u2008422-433, \u20082003.","DOI":"10.1038\/nrc1094"},{"key":"2022061620132026700_B23","doi-asserted-by":"crossref","unstructured":"Ortega N., Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J. Cell Sci., 115:\u20084201-4214, \u20082002.","DOI":"10.1242\/jcs.00106"},{"key":"2022061620132026700_B24","doi-asserted-by":"crossref","unstructured":"de Fraipont F., Nicholson A. C., Feige J. J., Van Meir E. G. Thrombospondins and tumor angiogenesis. Trends Mol. Med., 7:\u2008401-407, \u20082001.","DOI":"10.1016\/S1471-4914(01)02102-5"},{"key":"2022061620132026700_B25","doi-asserted-by":"crossref","unstructured":"Watnick R. S., Cheng Y. N., Rangarajan A., Ince T. A., Weinberg R. A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell, 3:\u2008219-231, \u20082003.","DOI":"10.1016\/S1535-6108(03)00030-8"},{"key":"2022061620132026700_B26","doi-asserted-by":"crossref","unstructured":"Dameron K. M., Volpert O. V., Tainsky M. A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Wash. DC), 265:\u20081582-1584, \u20081994.","DOI":"10.1126\/science.7521539"},{"key":"2022061620132026700_B27","doi-asserted-by":"crossref","unstructured":"Wen S., Stolarov J., Myers M. P., Su J. D., Wigler M. H., Tonks N. K., Durden D. L. PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. USA, 98:\u20084622-4627, \u20082001.","DOI":"10.1073\/pnas.081063798"},{"key":"2022061620132026700_B28","doi-asserted-by":"crossref","unstructured":"Volpert O. V., Pili R., Sikder H. A., Nelius T., Zaichuk T., Morris C., Shiflett C. B., Devlin M. K., Conant K., Alani R. M. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell, 2:\u2008473-483, \u20082002.","DOI":"10.1016\/S1535-6108(02)00209-X"},{"key":"2022061620132026700_B29","doi-asserted-by":"crossref","unstructured":"Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R. K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature (Lond.), 416:\u2008279-280, \u20082002.","DOI":"10.1038\/416279b"},{"key":"2022061620132026700_B30","doi-asserted-by":"crossref","unstructured":"Jimenez B., Volpert O. V., Crawford S. E., Febbraio M., Silverstein R. L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med., 6:\u200841-48, \u20082000.","DOI":"10.1038\/71517"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/5\/1570\/2523584\/zch00504001570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/5\/1570\/2523584\/zch00504001570.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:58:33Z","timestamp":1655413113000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/64\/5\/1570\/512333\/Thrombospondin-1-Associated-with-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,3,2]]},"published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-03-3126","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}